MEP13908A - 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations - Google Patents
6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparationsInfo
- Publication number
- MEP13908A MEP13908A MEP-139/08A MEP13908A MEP13908A ME P13908 A MEP13908 A ME P13908A ME P13908 A MEP13908 A ME P13908A ME P13908 A MEP13908 A ME P13908A
- Authority
- ME
- Montenegro
- Prior art keywords
- treatment
- alkenyl
- compounds
- alkinyl
- epoxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 102000004243 Tubulin Human genes 0.000 abstract 1
- 108090000704 Tubulin Proteins 0.000 abstract 1
- 230000003527 anti-angiogenesis Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229930013356 epothilone Natural products 0.000 abstract 1
- 150000003883 epothilone derivatives Chemical class 0.000 abstract 1
- 210000004907 gland Anatomy 0.000 abstract 1
- 210000003128 head Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 210000003739 neck Anatomy 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19921086A DE19921086A1 (de) | 1999-04-30 | 1999-04-30 | 6-Alkenyl- und 6-Alkinyl-Epothilon Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten |
| DE19954228A DE19954228A1 (de) | 1999-11-04 | 1999-11-04 | 6-Alkenyl-und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten |
| DE10015836A DE10015836A1 (de) | 2000-03-27 | 2000-03-27 | 6-Alkenyl- und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten |
| PCT/IB2000/000657 WO2000066589A1 (en) | 1999-04-30 | 2000-05-01 | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP13908A true MEP13908A (en) | 2010-06-10 |
Family
ID=27213767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-139/08A MEP13908A (en) | 1999-04-30 | 2000-05-01 | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1173441B1 (sr) |
| JP (2) | JP4024003B2 (sr) |
| KR (1) | KR100721488B1 (sr) |
| CN (1) | CN100368415C (sr) |
| AR (1) | AR023792A1 (sr) |
| AT (1) | ATE440847T1 (sr) |
| BG (1) | BG65601B1 (sr) |
| BR (1) | BR0010190A (sr) |
| CA (2) | CA2371226C (sr) |
| CY (1) | CY1109768T1 (sr) |
| CZ (1) | CZ299653B6 (sr) |
| DE (1) | DE60042821D1 (sr) |
| DK (1) | DK1173441T3 (sr) |
| EA (1) | EA011502B1 (sr) |
| EE (1) | EE05292B1 (sr) |
| ES (1) | ES2331506T3 (sr) |
| HK (1) | HK1046681B (sr) |
| HR (1) | HRP20010892A2 (sr) |
| HU (1) | HUP0201010A3 (sr) |
| IL (1) | IL145938A0 (sr) |
| ME (1) | MEP13908A (sr) |
| MX (1) | MXPA01011039A (sr) |
| NO (1) | NO328149B1 (sr) |
| NZ (1) | NZ514989A (sr) |
| PE (1) | PE20010116A1 (sr) |
| PL (1) | PL210762B1 (sr) |
| PT (1) | PT1173441E (sr) |
| RS (1) | RS51023B (sr) |
| SI (1) | SI1173441T1 (sr) |
| SK (1) | SK286858B6 (sr) |
| TW (2) | TWI280962B (sr) |
| WO (1) | WO2000066589A1 (sr) |
| ZA (1) | ZA200109859B (sr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0903348B2 (de) | 1995-11-17 | 2008-08-27 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Epothilon-Derivate und deren Herstellung |
| DE59712968D1 (de) | 1996-11-18 | 2008-10-30 | Biotechnolog Forschung Gmbh | Epothilone E und F |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| CA2273083C (en) | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
| US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
| US6518421B1 (en) * | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
| US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
| DE10020899A1 (de) * | 2000-04-20 | 2001-10-25 | Schering Ag | 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten |
| UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| SK8552003A3 (en) | 2001-01-25 | 2004-06-08 | Bristol Myers Squibb Co | Parenteral formulation containing epothilone analogs |
| NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| EP1938821B1 (en) | 2001-01-25 | 2016-03-30 | Bristol-Myers Squibb Company | Dosage forms of an epothilone analogue for the treatment of cancer |
| CN1610549A (zh) | 2001-02-20 | 2005-04-27 | 布里斯托尔-迈尔斯斯奎布公司 | 用于治疗难治肿瘤的埃坡霉素衍生物 |
| CA2438610A1 (en) | 2001-02-20 | 2002-08-29 | Francis Y. F. Lee | Treatment of refractory tumors using epothilone derivatives |
| HRP20030831B1 (en) | 2001-03-14 | 2012-08-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| JP2004532888A (ja) | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体 |
| EP1340498A1 (en) * | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
| AU2003218110A1 (en) | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C3-cyano epothilone derivatives |
| AU2003218107A1 (en) | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
| TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| US7008936B2 (en) | 2002-06-14 | 2006-03-07 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| RS20050235A (sr) | 2002-09-23 | 2007-06-04 | Bristol Myers Squibb Company, | Postupci za pripremanje,izolaciju i prečišćavanje epotilona b i kristalne strukture epotilona b dobijene primenom x-zraka |
| DE10361794B3 (de) * | 2003-12-31 | 2005-10-06 | Schering Ag | Optisch aktive heteroaromatische ß-Hydroxy-Ester und Verfahren zu deren Herstellung sowie deren Verwendung als Zwischenprodukte bei der Epothilon-Totalsynthese |
| EP1559447A1 (en) | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
| EP1640004A1 (en) * | 2004-09-24 | 2006-03-29 | Schering Aktiengesellschaft | Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| CN100384419C (zh) * | 2005-12-02 | 2008-04-30 | 菏泽睿鹰制药集团有限公司 | 一种埃坡霉素缓释植入组合物及应用 |
| DE102007016046A1 (de) | 2007-03-30 | 2008-10-23 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung |
| EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
| EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
| DE102007059752A1 (de) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone |
| EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
| MX2012013100A (es) | 2010-05-18 | 2013-01-22 | Cerulean Pharma Inc | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. |
| WO2013092998A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of antibodies |
| EP2872894B1 (en) | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
| WO2014072482A1 (en) | 2012-11-09 | 2014-05-15 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| EP2968582B1 (en) | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
| EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
| EP3010548A1 (en) | 2013-06-21 | 2016-04-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54115320A (en) * | 1978-02-28 | 1979-09-07 | Soda Aromatic | Novel unsaturated keto acid and its manufacture |
| JP2653663B2 (ja) * | 1988-02-15 | 1997-09-17 | 財団法人微生物化学研究会 | １．３―ジヒドロキシ―８―デセン―５―オンを含む免疫賦活剤及び制癌剤 |
| EP0469480A3 (en) * | 1990-08-01 | 1993-03-10 | Hoechst Aktiengesellschaft | Process for stereoselective preparation of 5-substituted delta-lactones and their use |
| WO1998038192A1 (de) * | 1997-02-25 | 1998-09-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Seitenkettenmodifizierte epothilone |
| EP1847540A1 (de) * | 1997-08-09 | 2007-10-24 | Bayer Schering Pharma Aktiengesellschaft | Neue Epothilonderivate, Herstellungsverfahren dafür und ihre pharmazeutische Verwendung |
-
2000
- 2000-04-28 PE PE2000000403A patent/PE20010116A1/es not_active Application Discontinuation
- 2000-04-28 AR ARP000102024A patent/AR023792A1/es active IP Right Grant
- 2000-05-01 EA EA200101025A patent/EA011502B1/ru not_active IP Right Cessation
- 2000-05-01 WO PCT/IB2000/000657 patent/WO2000066589A1/en not_active Ceased
- 2000-05-01 EE EEP200100568A patent/EE05292B1/xx not_active IP Right Cessation
- 2000-05-01 ES ES00922826T patent/ES2331506T3/es not_active Expired - Lifetime
- 2000-05-01 HR HR20010892A patent/HRP20010892A2/xx not_active Application Discontinuation
- 2000-05-01 SK SK1551-2001A patent/SK286858B6/sk not_active IP Right Cessation
- 2000-05-01 CZ CZ20013885A patent/CZ299653B6/cs not_active IP Right Cessation
- 2000-05-01 CN CNB008069786A patent/CN100368415C/zh not_active Expired - Fee Related
- 2000-05-01 PT PT00922826T patent/PT1173441E/pt unknown
- 2000-05-01 AT AT00922826T patent/ATE440847T1/de active
- 2000-05-01 EP EP00922826A patent/EP1173441B1/en not_active Expired - Lifetime
- 2000-05-01 HU HU0201010A patent/HUP0201010A3/hu unknown
- 2000-05-01 CA CA2371226A patent/CA2371226C/en not_active Expired - Fee Related
- 2000-05-01 DK DK00922826T patent/DK1173441T3/da active
- 2000-05-01 SI SI200031044T patent/SI1173441T1/sl unknown
- 2000-05-01 JP JP2000615619A patent/JP4024003B2/ja not_active Expired - Fee Related
- 2000-05-01 IL IL14593800A patent/IL145938A0/xx unknown
- 2000-05-01 HK HK02108204.3A patent/HK1046681B/zh not_active IP Right Cessation
- 2000-05-01 RS YUP-776/01A patent/RS51023B/sr unknown
- 2000-05-01 KR KR1020017013840A patent/KR100721488B1/ko not_active Expired - Fee Related
- 2000-05-01 PL PL351491A patent/PL210762B1/pl not_active IP Right Cessation
- 2000-05-01 BR BR0010190-7A patent/BR0010190A/pt not_active IP Right Cessation
- 2000-05-01 DE DE60042821T patent/DE60042821D1/de not_active Expired - Lifetime
- 2000-05-01 NZ NZ514989A patent/NZ514989A/xx not_active IP Right Cessation
- 2000-05-01 MX MXPA01011039A patent/MXPA01011039A/es active IP Right Grant
- 2000-05-01 ME MEP-139/08A patent/MEP13908A/xx unknown
- 2000-05-01 CA CA2651653A patent/CA2651653C/en not_active Expired - Fee Related
- 2000-05-18 TW TW89108133A patent/TWI280962B/zh not_active IP Right Cessation
- 2000-05-18 TW TW095145399A patent/TWI294292B/zh not_active IP Right Cessation
-
2001
- 2001-10-26 BG BG106053A patent/BG65601B1/bg unknown
- 2001-10-29 NO NO20015278A patent/NO328149B1/no not_active IP Right Cessation
- 2001-11-29 ZA ZA200109859A patent/ZA200109859B/xx unknown
-
2007
- 2007-04-11 JP JP2007104224A patent/JP4886578B2/ja not_active Expired - Fee Related
-
2009
- 2009-11-25 CY CY20091101237T patent/CY1109768T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP13908A (en) | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | |
| Taha et al. | Synthesis of benzimidazole derivatives as potent β-glucuronidase inhibitors | |
| PL309392A1 (en) | 7-halide and 7beta, 8beta-methane taxoles, their antineoplastic application and pharmaceutical compositions containing them | |
| WO2022008627A3 (en) | Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof | |
| Gu et al. | Synthesis and antitumor activity of α-aminophosphonates containing thiazole [5, 4-b] pyridine moiety | |
| WO2007044729A3 (en) | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | |
| EP0982302A3 (en) | Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them | |
| HUP9901894A2 (hu) | Eljárás kurkuminnal rokon vegyületek előállítására | |
| Shi et al. | Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista | |
| Liu et al. | Anticancer sulfonamide hybrids that inhibit bladder cancer cells growth and migration as tubulin polymerisation inhibitors | |
| MX9700026A (es) | Analogos de 7-eter-taxol, su uso antineoplastico y composiciones farmaceuticas que los contienen. | |
| DE602004023271D1 (de) | Metastin derivate und ihre verwendung | |
| PE20081058A1 (es) | Proceso para la flotacion de menas del tipo de sulfuros | |
| Zhang et al. | A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin | |
| ATE502025T1 (de) | Arylcarboxamide und ihre verwendung als antitumormittel | |
| AR063417A1 (es) | Compuestos inhibidores del activador de plasminogeno tipo 1(pai-1) | |
| Malarz et al. | Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations | |
| EP4516737A4 (en) | METHOD FOR SYNTHESIZING SEVERAL KILOGRAMS OF SILICON CARBIDE POWDER | |
| Das et al. | 3-(3, 4, 5-Trimethoxyphenyl)-1-oxo-2-propene: A novel pharmacophore displaying potent multidrug resistance reversal and selective cytotoxicity | |
| CN109206399B (zh) | 三级酰胺微管蛋白聚合抑制剂及其制备方法和应用 | |
| Wang et al. | 2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic acids as novel selective histone deacetylase-6 inhibitors with antiproliferative activity | |
| Zheng et al. | 1, 2, 3-Triazole-Dithiocarbamate hybrids, a group of novel cell active SIRT1 inhibitors | |
| Yu et al. | Design, synthesis, and in vitro anticancer activity of novel chrysin derivatives | |
| Bhat et al. | Targeting HER-2 over expressed breast cancer cells with 2-cyclohexyl-N-[(Z)-(substituted phenyl/furan-2-yl/thiophene-2-yl) methylidene] hydrazinecarbothioamide | |
| Islim et al. | Exploring the anticancer potential of nitrated N-substituted-4-hydroxy-2-quinolone-3-carboxamides: synthesis, biological assessment, and computational analysis |